louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01292109: A Study of PICOPREP in Patients Needed to Clean the Bowel Prior to X-ray Examination, Endoscopy or Surgery.
Official title: Compliance and Efficacy in the Use of PICOPREP for Bowel Cleansing
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Bowel Cleanliness
Keywords: endoscopy
colonoscopy
preparation for surgery
Lead sponsor: Ferring Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2011-02-09
Enrollment: 252
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients about to undergo X-ray examination, endoscopy or surgery.

Brief summary: The study serves as a confirmation of safety, tolerance and efficacy of PICOPREP in clinical practice.


Eligibility criteria: Inclusion Criteria:

* Patients receiving PICOPREP® for bowel evacuation prior to endoscopy or surgery

Exclusion Criteria:

* Patients in which prescription of PICOPREP® is contraindicated

Primary outcomes:
measure: Documentation of use PICOPREP in everyday practice
timeFrame: Day 0 - 2
Secondary outcomes:
measure: Participant satisfaction and compliance after bowel cleansing
timeFrame: Days 0-2
measure: Participants with adverse events reported by frequency and severity
timeFrame: Days 1-2
Other outcomes:
Locations:
city: Ostrava - Poruba
country: Czech Republic
facility: University Hospital
city: Pilsen
country: Czech Republic
facility: University Hospital
city: Prague 7
country: Czech Republic
facility: Iscare - Prague 7
Study officials:
affiliation: Ferring Pharmaceuticals
name: Clinical Development Support
role: STUDY_DIRECTOR
References:
Clinical trial NCT04486209: Non-invasive Spinal Cord Stimulation for Spasticity Control and Augmentation of Voluntary Motor Control in Individuals With Multiple Sclerosis
Official title: Non-invasive Spinal Cord Stimulation for Spasticity Control and Augmentation of Voluntary Motor Control in Individuals With Multiple Sclerosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Multiple Sclerosis
Keywords: neuromodulation
spinal cord stimulation
walking function
spasticity
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
Collaborators: name: Neurological Center, Otto Wagner Hospital
First posted: 2020-07-24
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Epidural spinal cord stimulation (SCS) is currently regarded as one of the most promising intervention methods to improve motor function in individuals with severe spinal cord injury. In parallel, an increasing number of studies is suggesting that noninvasive SCS can improve spasticity and residual motor control in the same subject population. The present study explores whether single sessions of noninvasive SCS would improve walking performance and ameliorate spasticity in individuals with multiple sclerosis.


Eligibility criteria: Inclusion Criteria:

* confirmed diagnosis of relapsing-remitting, primary- or secondary-progressive MS
* lower-limb spasticity

Exclusion Criteria:

* acute relapse of MS
* other neuromuscular diseases
* active and passive implants at vertebral level T9 or caudally
* dermatological issues at stimulation site
* pregnancy

Primary outcomes:
measure: Modified Ashworth Scale
timeFrame: 24 hours
Secondary outcomes:
measure: 10-m walk test
timeFrame: 24 hours
measure: 2-min walk test
timeFrame: 24 hours
measure: Timed up an go test
timeFrame: 24 hours
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Medical University of Vienna
Study officials:
References:
Clinical trial NCT00839709: Peripheral Immunologic Response of Solid Organ Transplant Recipients to Depletion Versus Non-depletion Protocols
Official title: Peripheral Immunologic Response of Solid Organ Transplant Recipients to Depletion vs. Non-depletion Protocols
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Liver Disease
Liver Transplantation
Keywords: liver disease
liver transplantation
depletion immunosuppression
non-depletion immunosuppression
Lead sponsor: University of Washington
Sponsor class: OTHER
First posted: 2009-02-09
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: liver transplant recipients

Brief summary: Rejection and infection are primary causes of morbidity and mortality in solid organ transplant recipients. Current clinical practice relies on immunosuppressive drug levels measured in plasma to reflect the peripheral immune response in solid organ transplant recipients. Direct measurement of the number and functions of the immune cells themselves using multi-parameter flow cytometry may enable individualized immunosuppression management for organ transplant recipients. Multi-parameter flow cytometry will be used to compare levels and functional capabilities of multiple lymphocyte subsets between cohorts of patients receiving depletion induction and those receiving a non-depletion regimen. The activation state, cytotoxic potential and the functional capabilities of these cells will be examined within patients over the first six months post transplant.


Eligibility criteria: Inclusion Criteria:

* liver transplant recipient

Exclusion Criteria:

* none

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Seattle
country: United States
facility: University of Washington
state: Washington
Study officials:
affiliation: University of Washington
name: Jorge D Reyes, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02673307: Chewing Gum and Gastric Emptying of Water
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Comparison of Gastric Emptying Rate of Water When Chewing Gum or Not
Lead sponsor: Hôpital Edouard Herriot
Sponsor class: OTHER
First posted: 2016-02-03
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The aims of this prospective cross over study was to compare the gastric emptying of 250 ml water in fasting volunteers, in two situations : without chewing gum or while chewing gum during 45 min


Eligibility criteria: Inclusion Criteria:

* ASA 1 or 2 volunteers

Exclusion Criteria:

* digestive diseases, gastroparesis
* Smokers
* Pregnancy
* Diabetes Mellitus
* Medication affecting gastric motility
* Previous gastrointestinal surgery

Primary outcomes:
measure: Comparison of the rate of gastric emptying of 250 ml water when chewing or not chewing gum, as assessed by the ultrasound measurement of antral area performed each 20 min
timeFrame: every 20 minutes during 120 min
Secondary outcomes:
Other outcomes:
Locations:
city: Bron
country: France
facility: Hopital Femme Mère Enfant - Hospices Civils de Lyon
Study officials:
affiliation: Hospices Civils de Lyon
name: Lionel BOUVET, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bouvet L, Loubradou E, Desgranges FP, Chassard D. Effect of gum chewing on gastric volume and emptying: a prospective randomized crossover study. Br J Anaesth. 2017 Nov 1;119(5):928-933. doi: 10.1093/bja/aex270.
Clinical trial NCT03533907: Pregnancy Outcomes in Infertile Patients After Treatment With Ulipristal Acetate.
Official title: Pregnancy Outcomes in Infertile Patients After Treatment With Ulipristal Acetate: Preliminary Academic Assisted Reproductive Technology Center Experience.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Myoma;Uterus
Infertility, Female
Lead sponsor: Istituto Clinico Humanitas
Sponsor class: OTHER
First posted: 2018-05-23
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The women included were patients of the Humanitas Fertility Center; they all had a diagnosis of infertility and were trying to become pregnant. They received ≥1 month of therapy with UA 5 mg/day over the period 2013 - 2018

Brief summary: The investigators analyzed a group of infertile women treated with Ulipristal Acetate (UA) for uterine fibroids at the Humanitas Fertility Center. All the patients' data were extracted from the Fertility Center external-audit-anonymized electronic research query system.

Detailed description: In the recent years several large studies have been published on the efficacy of Ulipristal Acetate treatment of moderate to severe symptoms of uterine fibroids in adult women: initially proposed only as pre-surgical treatment, the UA was subsequently also used for the long-term treatment of uterine myomas symptoms.

However, few data are available on the effects of UA in terms of increasing fecundability, implantation and pregnancy outcome and safety in the general population, and in infertile patients in particular.

This retrospective study aims at describing the correlation between the use of Ulipristal Acetate and pregnancy outcome in infertile patients and at comparing the UA plus surgery approach to the UA-only treatment in terms of pregnancy outcome.

Eligibility criteria: Inclusion Criteria:

* infertile women received at least 1 month of therapy with UA 5 mg/day for uterine fibroids
* more of 1 year of active pregnancy seeking

Exclusion:

* menopausal women;

Primary outcomes:
measure: implantation rate
timeFrame: 2013 - 2018
Secondary outcomes:
measure: myomas reduction
timeFrame: 2013 - 2018
Other outcomes:
Locations:
city: Rozzano
country: Italy
facility: Paolo Emanuele Levi Setti
state: MI
Study officials:
References:
citation: Luyckx M, Squifflet JL, Jadoul P, Votino R, Dolmans MM, Donnez J. First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids. Fertil Steril. 2014 Nov;102(5):1404-9. doi: 10.1016/j.fertnstert.2014.07.1253. Epub 2014 Sep 17.
citation: Donnez J, Donnez O, Matule D, Ahrendt HJ, Hudecek R, Zatik J, Kasilovskiene Z, Dumitrascu MC, Fernandez H, Barlow DH, Bouchard P, Fauser BC, Bestel E, Loumaye E. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil Steril. 2016 Jan;105(1):165-173.e4. doi: 10.1016/j.fertnstert.2015.09.032. Epub 2015 Oct 23.
Clinical trial NCT06037707: Thromboembolic Complications in COVID-19 Patients in Intensive Care Unit
Official title: Incidence of Thromboembolism in COVID-19 Infection in the ICU: a Retrospective Cohort Analysis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID-19-Associated Thromboembolism
Keywords: COVID-19
thromboembolism
Variants of COVID-19
Lead sponsor: Derince Training and Research Hospital
Sponsor class: OTHER
First posted: 2023-09-14
Enrollment: 484
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Study Population of the present study is all of the patients diagnosed with COVID-19 and admitted to the intensive care units at Derince Training and Research Hospital at the time of between 1-March-2020 and 31-December-2021in

Brief summary: The present study aims to determine frequency of thromboembolic complications and the underlying causes of this complication of the patients who admitted to the intensive care unit diagnosed with COVID-19.

Detailed description: Patients diagnosed with COVID-19 infection and admitted to the ICU were recruited. Demographic information, comorbidities, length of ICU stay, some laboratory data,thromboembolic complications of the patients were recorded.

Eligibility criteria: Inclusion Criteria:

* Patients who were infected with COVID-19 and admitted to the intensive care unit between the time of March 2020-December 2021

Exclusion Criteria:

* who is under 18 years old.

Primary outcomes:
measure: Rate of thromboembolic complications among patients who effected from different variants of COVID-19 Disease
timeFrame: During the entire intensive care stay up to 1 day
Secondary outcomes:
measure: Rate of thromboembolic complications of COVID-19 disease in critically ill patients
timeFrame: During the entire intensive care stay up to 1 day
measure: Rate of thromboembolic complications according to anticoagulant therapy
timeFrame: During the entire intensive care stay up to 1 day
measure: What is the rate of thromboembolism according to the comorbidities
timeFrame: During the entire intensive care stay up to 1 day
Other outcomes:
Locations:
city: Kocaeli
country: Turkey
facility: Derince Research and Training Hospital
state: Derince
Study officials:
affiliation: Health and Science University Hamidiye Institute of Health Sciences
name: Berna Karakoyun Lacin, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05023707: Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia
Official title: Pilot Study of the Safety and Efficacy of Anti-FLT3 Chimeric Antigen Receptor Engineered T-Cells in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Acute Myeloid Leukemia
Keywords: FLT3,CAR-T,AML
Lead sponsor: The First Affiliated Hospital of Soochow University
Sponsor class: OTHER
Collaborators: name: The First Affiliated Hospital with Nanjing Medical University
name: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
name: The Second People's Hospital of Huai'an
name: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
First posted: 2021-08-26
Enrollment: 5
Sex: ALL
Minimum age (years): 16
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a prospective,open-label, phase1/2 study to evaluate the safety and efficacy of anti-FLT3 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of FLT3 positive relapsed or refractory acute myeloid leukemia.

Detailed description: The patients will receive infusion of anti-FLT3 CAR T-cells targeting FLT3 to evaluate the safety and efficacy of anti-FLT3 CAR T-Cells in relapsed or refractory acute myeloid leukemia.

Eligibility criteria: Inclusion Criteria:

* FLT3 positive relapsed/refractory acute myeloid leukemia
* Age 16-65 years.
* Left ventricular ejection fractions ≥ 0.5 by echocardiography
* Creatinine \< 1.5x upper limit of normal.
* Aspartate aminotransferase/aspartate aminotransferase ≤ 2.5x upper limit of normal
* Total bilirubin ≤ 1.5x upper limit of normal
* Karnofsky performance status ≥ 60
* Expected survival time ≥ 3 months (according to investigator's judgement)

Exclusion Criteria:

* Patients are pregnant or lactating
* Uncontrolled active infection
* Grade III/IV cardiovascular disability according to the New York Heart
* Association Classification
* Active hepatitis B or hepatitis C infection
* Patients with HIV infection
* Patients with a history of seizure
* Patients with other contraindications considered unsuitable for participation in this study (according to investigator's judgement)

Primary outcomes:
measure: Number of Adverse Events
timeFrame: 12 months
Secondary outcomes:
measure: Overall response rate (ORR)
timeFrame: 2 years
measure: Event-free survival (EFS)
timeFrame: 2 years
measure: Cumulative incidence of relapse(CIR)
timeFrame: 2 years
Other outcomes:
Locations:
city: Suzhou
country: China
facility: The First Affiliated Hospital of Soochow University
state: Jiangsu
Study officials:
affiliation: The First Affiliated Hospital of Soochow University
name: Xiaowen Tang, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05682807: Effect of Caffeine Versus Probiotic on Preterm Neonates With Bronchopulmonary Dysplasia
Official title: Caffeine Versus Probiotic as Adjuvant Therapy for Preterm Neonates With Bronchopulmonary Dysplasia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Bronchopulmonary Dysplasia
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2023-01-12
Enrollment: 90
Sex: ALL
Minimum age (years): 0
Maximum age (years): 37
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to evaluate the effectiveness of caffeine versus probiotics supplementation as adjuvant therapy for preterm neonates with Bronchopulmonary dysplasia (BPD).


Eligibility criteria: Inclusion Criteria:

* Male and female preterm neonates less than 37 weeks gestational age.
* Suffering from Bronchopulmonary dysplasia (BPD) diagnosed as follow:
* History: Preterm infant with persistence oxygen dependency up to 28 days of life.
* Clinical signs: increase work of breathing, increase oxygen requirements , increase in apnea , bradycardia and retraction.
* Laboratory: arterial blood gases and electrolytes.
* Radiology: streaky interstitial markings, patchy atelectasis , intermingled with cystic areas and severe lung hyperinflation.

Exclusion Criteria:

* Term and post term neonates
* Neonates with congenital infections
* Neonates with major congenital anomalies

Primary outcomes:
measure: Complete blood count
timeFrame: 2 months
measure: Kidney function test
timeFrame: 2 months
measure: Liver function test
timeFrame: 2 months
measure: Inflammatory parameter
timeFrame: 2 months
Secondary outcomes:
measure: change in Serum Tumor necrosis factor alpha (TNF-α)
timeFrame: 2 months
measure: change in serum transforming growth factor (TGF)-β.
timeFrame: 2 months
measure: change in Serum superoxide dismutase (SOD)
timeFrame: 2 months
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Tanta University
state: El Gharbia
Study officials:
References:
Clinical trial NCT00589407: Unilateral Blindness/ Unilateral Deafness-relation to Neck Pain
Official title: Unilateral Blindness/ Unilateral Deafness-relation to Neck Pain
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Neck Pain
Unilateral Blindness
Unilateral Deafness
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2008-01-09
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: study group: patients with unilateral blindness and unilateral deafness as the control group: patients attending the eye ENT clinics for other reasons as control

Brief summary: Neck pain is a common complaint in the general population affecting 10-15% of the general population. females more than men. Known risk factors are: Trauma, Repetitive lifting of heavy objects at work, driving vibrating vehicles, frequents diving from boards and smoking. No study dealt with the possible role of unilateral loss of vision or hearing as a risk factor for the development of neck pain. Intuitively, one might suspect that unilateral blindness or deafness will lead to a tilted position of the head, in order to cover a better visual/audio field. This position, in time, might lead to the development of neck pain.

Our hypothesis is that patients with unilateral blindness/deafness will suffer from neck pain more frequently than the general population.


Eligibility criteria: Inclusion criteria:

* Men and women suffering from unilateral blindness or deafness
* Men and women visiting the ophthalmology or ENT clinics (general population) for reasons other than unilateral blindness/deafness and agreeing to participate in the study.
* Over 18 years of age
* Signed informed consent

Exclusion criteria:

* Subjects suffering from neck pain as a result of fractures, infection, or metastatic disease.
* Inability to understand or fill out the questionnaire/informed consent.

Primary outcomes:
measure: neck pain
timeFrame: two weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hadassah Medical Organization.
Study officials:
affiliation: Hadassah Medical Organization
name: Yair Barzilay
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05951907: The Anesthetic Efficacy of Lidocaine and Articaine as Buccal Injection for Maxillary Premolar Teeth Extraction.
Official title: The Anesthetic Efficacy of Articaine as Buccal Injection Compared to Lidocaine Baccual and Palatal Injection for Maxillary Premolar Teeth Extraction A Randomized, Single-Blinded, Clinical Trial.
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Anesthesia, Local
Lead sponsor: University of Baghdad
Sponsor class: OTHER
First posted: 2023-07-19
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Case-Control
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study Is designed as a prospective randomized, single-blinded clinical trial. To evaluate The anesthetic efficacy of articaine as a buccal Injection for maxillary premolar teeth extraction, compared to lidocaine as a buccal and palatal injection.

Detailed description: In the current study, the sample size (200) patients were distributed into two groups, group (A), 100 patients extracted upper premolar teeth by using 1.8 mL cartridges of 4% articaine hydrochloride with 1:100,000 epinephrine (Artheek, Colombia) as a buccal injection without palatal injection, and Group (B), 100 patients were removed upper premolar teeth by using Injectable local anesthetic agents included; 1.8 mL cartridges of 2% lidocaine hydrochloride with 1:80,000 epinephrine (Huons, Korea) as a buccal and palatal injection, the pain assessment after extraction was assessed by using (vas) visual analog scale, comparison between the outcomes by the two groups were evaluated, according to many variables (age, gender, extracted tooth, type of anesthesia, extraction duration).

Eligibility criteria: Inclusion Criteria:

1. Patients ≥ 16 years old, including both genders.
2. Patients indicated for extraction of one of the maxillary premolar's teeth.

Exclusion Criteria:

1. Patients who were allergic to the local anesthetic agents used in this study.
2. Patients who presented with acute periapical infections.
3. Patients who required surgical extraction that entails flap reflection and bone removal.
4. Pregnant patients.
5. Patients with uncontrolled systemic diseases.
6. Patients are taking medications affecting pain assessment, like opioids.

Primary outcomes:
measure: Pain during Extraction
timeFrame: Assessment of pain in the period during which the extraction has been made and up to 5 minutes after extraction of the tooth.
Secondary outcomes:
Other outcomes:
Locations:
city: Baghdad
country: Iraq
facility: Almustafa Qays
state: Almansour
Study officials:
affiliation: College of Dentistry - University of Baghdad
name: Hasanain A. Al-Jumaily, C.A.B.M.S
role: STUDY_DIRECTOR
References: